Merck & Co. Inc. (MRK)

76.73
NYSE : Health Technology
Prev Close 76.69
Day Low/High 76.40 / 77.35
52 Wk Low/High 65.25 / 92.64
Avg Volume 10.41M
Exchange NYSE
Shares Outstanding 2.52B
Market Cap 198.70B
EPS 3.80
P/E Ratio 19.58
Div & Yield 2.44 (2.95%)
This Isn't a Bearish Pause in the Market

This Isn't a Bearish Pause in the Market

It's simply a little consolidation after a huge run. But could it develop?

Intermediate Trade: Merck

Intermediate Trade: Merck

I prefer this MRK bearishly biased, vertical put spread expiring in June.

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

The Good, the Bad and the Ugly (2:30 PM Edition)

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...

Midday Report: Pharma Stocks Jump on Trump Win; Nasdaq Plummets

Midday Report: Pharma Stocks Jump on Trump Win; Nasdaq Plummets

Wall Street ran at two speeds with the Dow Jones Industrial Average setting a record high earlier in the day while the Nasdaq plummeted into the red.

Cramer: Health Care Stocks and Banks Could Be Trump Winners

Cramer: Health Care Stocks and Banks Could Be Trump Winners

But don't buy blindly. There are too many companies that can be retaliated against.

My Takeaways and Observations

"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax.   A consecutive nine-day market drop was snapped as we regained most that was lost in that period.   Today was a great day. (Boy, would I like to annualize the pe...

Cramer: Let's Look Beyond the Ballot Box

Cramer: Let's Look Beyond the Ballot Box

After the election passes we are going to talk about companies again -- and these have done well.

Cramer: 9 Stocks to Watch if We Get a Midday Lull

Cramer: 9 Stocks to Watch if We Get a Midday Lull

Avoid stocks with poor numbers that would suffer under a Clinton administration.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

Another Sign of a Market Drop

Another Sign of a Market Drop

S&P drops below key level.

Put Merck on Your Holiday Shopping List

Put Merck on Your Holiday Shopping List

An opportunity may actually come before Thanksgiving.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

Cramer: Here's the Secret to Driving Stocks Higher in This Market

Cramer: Here's the Secret to Driving Stocks Higher in This Market

Posting results 'not as a bad as we thought' has become a successful strategy. It worked for Bristol.

Scynexis: Small Biopharma, Big Potential

Scynexis: Small Biopharma, Big Potential

This small-cap firm has a lot going for it.

Intermediate Trade: Bristol-Myers

Intermediate Trade: Bristol-Myers

The pharmaceutical giant has reason to be optimistic about its earnings release tomorrow.

Scanning the Earnings Universe, Plus Overnight Tidbits

Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...

Markets Await Apple Earnings on Tuesday

Markets Await Apple Earnings on Tuesday

On Tuesday, October 25, Apple reports fiscal fourth quarter results after the markets close.

Technical Picture Remains Mixed

Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...

It's Not Easy Being Green: 3 Solid Names That Stand Out

It's Not Easy Being Green: 3 Solid Names That Stand Out

Look for solid companies showing life.

Merck upgraded at Merrill

Merck's Breakout Is Just Getting Started

Merck's Breakout Is Just Getting Started

The stock's healthy recent pattern appears to be giving way to a fresh bull leg.

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Merck to Discontinue Osteoporosis Drug Development

Merck to Discontinue Osteoporosis Drug Development

Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.

Intermediate Trade: Merck

Intermediate Trade: Merck

The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.

Cramer: The 'Just You Wait' Crowd Keeps Waiting

Cramer: The 'Just You Wait' Crowd Keeps Waiting

The market continues to defy those players who believe we are seeing the calm before the storm.